{"id":"talaporfin","rwe":[{"pmid":"41638379","year":"2026","title":"Phase I/II clinical study of next-generation photodynamic therapy (L-PDT) using talaporfin sodium (Laserphyrin®) for cervical intraepithelial neoplasia: Efficacy, safety, and fertility preservation.","finding":"","journal":"Photodiagnosis and photodynamic therapy","studyType":"Clinical Study"},{"pmid":"41569684","year":"2026","title":"Clinical benefits of photodynamic therapy in glioblastoma: systematic review and meta-analysis.","finding":"","journal":"Journal of neurosurgery","studyType":"Clinical Study"},{"pmid":"41545814","year":"2026","title":"Treatment resistance factors associated with Talaporfin sodium photodynamic therapy for local control after chemoradiotherapy for esophageal cancer.","finding":"","journal":"Esophagus : official journal of the Japan Esophageal Society","studyType":"Clinical Study"},{"pmid":"41463401","year":"2025","title":"Talaporfin Sodium as a Clinically Translatable Radiosensitizer in Radiodynamic Therapy.","finding":"","journal":"Biomolecules","studyType":"Clinical Study"},{"pmid":"41328291","year":"2025","title":"A Multicenter Phase II Study on Photodynamic Therapy Using Talaporfin Sodium (ME2906) and a Semiconductor Laser (PNL6405CIN) for Intraepithelial Tumors of the Cervix.","finding":"","journal":"Reproductive medicine and biology","studyType":"Clinical Study"}],"tags":[{"label":"talaporfin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Malignant tumor of lung","category":"indication"},{"label":"Primary malignant neoplasm of brain","category":"indication"},{"label":"Meiji Seika Pharm","category":"company"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Dermatologic Agents","category":"pharmacology"},{"label":"Photosensitizing Agents","category":"pharmacology"},{"label":"Radiation-Sensitizing Agents","category":"pharmacology"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"Meiji Seika Pharm","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=TALAPORFIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:14:45.230117+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:14:51.587973+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TALAPORFIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:14:51.911181+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2111186/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:14:52.621283+00:00"}},"allNames":"laserphyrin","offLabel":[],"synonyms":["talaporfin tetrasodium","ME-2906","NPe-6","talaporfin sodium","laserphyrin","talaporfin","N-Aspartyl chlorin e6"],"timeline":[{"date":"2003-10-26","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Meiji Seika Pharm)"}],"approvals":[{"date":"2003-10-26","orphan":false,"company":"Meiji Seika Pharm","regulator":"PMDA"}],"brandName":"Laserphyrin","ecosystem":[{"indication":"Malignant tumor of lung","otherDrugs":[{"name":"doxorubicin","slug":"doxorubicin","company":""},{"name":"mechlorethamine","slug":"mechlorethamine","company":"Recordati Rare"},{"name":"methotrexate","slug":"methotrexate","company":"Dava Pharms Inc"}],"globalPrevalence":null},{"indication":"Primary malignant neoplasm of brain","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"modality":"Small Molecule","drugClass":"talaporfin","explanation":"","oneSentence":"","technicalDetail":"Talaporfin generates reactive oxygen species (ROS) through a type II photodynamic reaction, leading to cell death via apoptosis or necrosis."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2555","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=TALAPORFIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TALAPORFIN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:47:42.950384","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:14:54.484729+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"talaporfin","indications":{"approved":[{"name":"Malignant tumor of lung","source":"DrugCentral","snomedId":363358000,"regulator":"FDA"},{"name":"Primary malignant neoplasm of brain","source":"DrugCentral","snomedId":93727008,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01924273","phase":"PHASE1","title":"Novel Treatment for Port Wine Stain Birthmarks","status":"COMPLETED","sponsor":"University of California, Irvine","startDate":"2013-06","conditions":["Port-Wine Stain"],"enrollment":7,"completionDate":"2017-07-03"},{"nctId":"NCT02326454","phase":"PHASE2","title":"A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia","status":"COMPLETED","sponsor":"Light Sciences Oncology","startDate":"2014-11","conditions":["Benign Prostatic Hyperplasia"],"enrollment":225,"completionDate":"2017-03-29"},{"nctId":"NCT00440310","phase":"PHASE3","title":"Phase 3 Trial of Litx™ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases","status":"COMPLETED","sponsor":"Light Sciences Oncology","startDate":"2007-02","conditions":["Liver Metastases","Colorectal Neoplasms","Neoplasm Metastasis","Neoplasm Recurrence, Local"],"enrollment":483,"completionDate":"2011-10"},{"nctId":"NCT00716469","phase":"PHASE1","title":"Phase I Clinical Study of the Safety of Photodynamic Therapy (PDT) Using LS11 in Children With Plexiform Neurofibromas","status":"TERMINATED","sponsor":"Children's Hospital of Philadelphia","startDate":"2008-07","conditions":["Neurofibroma"],"enrollment":7,"completionDate":"2012-07"},{"nctId":"NCT00355355","phase":"PHASE3","title":"A Phase 3 Study of Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC)","status":"COMPLETED","sponsor":"Light Sciences Oncology","startDate":"2006-07","conditions":["Carcinoma, Hepatocellular","Liver Neoplasms"],"enrollment":208,"completionDate":"2012-09"},{"nctId":"NCT00409214","phase":"PHASE2","title":"Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma","status":"COMPLETED","sponsor":"Light Sciences Oncology","startDate":"2006-11","conditions":["Glioma","Glioblastoma Multiforme","Anaplastic Astrocytoma"],"enrollment":18,"completionDate":""},{"nctId":"NCT00709488","phase":"PHASE1","title":"Phase 1 Study of the Litx™ BPH System in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)","status":"COMPLETED","sponsor":"Light Sciences Oncology","startDate":"2008-06","conditions":["Benign Prostatic Hyperplasia","Lower Urinary Tract Symptoms"],"enrollment":12,"completionDate":"2011-04"},{"nctId":"NCT00918034","phase":"PHASE2","title":"Study of Light-Activated Talaporfin Sodium in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)","status":"COMPLETED","sponsor":"Light Sciences Oncology","startDate":"2009-05","conditions":["Benign Prostatic Hyperplasia","Lower Urinary Tract Symptoms"],"enrollment":21,"completionDate":"2011-02"},{"nctId":"NCT00102115","phase":"PHASE1","title":"Study of Talaporfin Sodium Photodynamic Therapy to Treat Advanced Age Related Macular Disease","status":"TERMINATED","sponsor":"Light Sciences LLC","startDate":"2004-12","conditions":["Macular Degeneration","Choroidal Neovascularization"],"enrollment":27,"completionDate":"2006-01"},{"nctId":"NCT00122876","phase":"PHASE1,PHASE2","title":"Tumor Ablation With Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC)","status":"COMPLETED","sponsor":"Light Sciences Oncology","startDate":"2005-04","conditions":["Carcinoma, Hepatocellular","Liver Neoplasms"],"enrollment":25,"completionDate":"2006-10"},{"nctId":"NCT00083785","phase":"PHASE2","title":"Study of the Litx™ System Combined With Chemotherapy in Patients With Colorectal Liver Metastases","status":"COMPLETED","sponsor":"Light Sciences LLC","startDate":"2004-05","conditions":["Liver Metastasis","Colorectal Neoplasms","Liver Neoplasms","Neoplasm Metastasis"],"enrollment":25,"completionDate":""},{"nctId":"NCT00068068","phase":"PHASE2","title":"Photodynamic Therapy With Talaporfin Sodium (LS11) in Treating Patients With Refractory Colorectal Liver Metastases","status":"COMPLETED","sponsor":"Light Sciences LLC","startDate":"2003-10","conditions":["Liver Metastasis","Colorectal Neoplasms","Liver Neoplasms","Neoplasm Metastasis"],"enrollment":25,"completionDate":""},{"nctId":"NCT00028405","phase":"PHASE1","title":"Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors","status":"COMPLETED","sponsor":"Light Sciences LLC","startDate":"2001-11","conditions":["Liver Metastasis","Pelvic Cancer","Head and Neck Cancer","Sarcoma","Rectal Cancer","Breast Cancer","Colorectal Cancer","Mouth Cancer"],"enrollment":48,"completionDate":"2002-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"P4ROX5ELT2","CHEBI":"CHEBI:135875","INN_ID":"7974","UMLSCUI":"C0245194","chemblId":"CHEMBL2111186","ChEMBL_ID":"CHEMBL2111186","KEGG_DRUG":"D01985","DRUGBANK_ID":"DB11812","PUBCHEM_CID":"5488036","SECONDARY_CAS_RN":"220201-34-3","MESH_SUPPLEMENTAL_RECORD_UI":"C053434"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Meiji Seika Pharm","relationship":"Current Owner"}],"publicationCount":196,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[{"date":"2026 Feb 2","pmid":"41638379","title":"Phase I/II clinical study of next-generation photodynamic therapy (L-PDT) using talaporfin sodium (Laserphyrin®) for cervical intraepithelial neoplasia: Efficacy, safety, and fertility preservation.","journal":"Photodiagnosis and photodynamic therapy"},{"date":"2026 Jan 16","pmid":"41569684","title":"Clinical benefits of photodynamic therapy in glioblastoma: systematic review and meta-analysis.","journal":"Journal of neurosurgery"},{"date":"2026 Jan 16","pmid":"41545814","title":"Treatment resistance factors associated with Talaporfin sodium photodynamic therapy for local control after chemoradiotherapy for esophageal cancer.","journal":"Esophagus : official journal of the Japan Esophageal Society"},{"date":"2025 Dec 18","pmid":"41463401","title":"Talaporfin Sodium as a Clinically Translatable Radiosensitizer in Radiodynamic Therapy.","journal":"Biomolecules"},{"date":"2025 Jan-Dec","pmid":"41328291","title":"A Multicenter Phase II Study on Photodynamic Therapy Using Talaporfin Sodium (ME2906) and a Semiconductor Laser (PNL6405CIN) for Intraepithelial Tumors of the Cervix.","journal":"Reproductive medicine and biology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Meiji Seika Pharm","companyId":"meiji-seika-pharm","modality":"Small molecule","firstApprovalDate":"2015","aiSummary":"Laserphyrin, also known as talaporfin sodium, is a small molecule used in the treatment of various conditions, including Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms, and certain types of cancer. It has been studied in clinical trials using different interventions, including the placement of a device in the prostate urethra and transurethral illumination with light emitting diodes.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2003-10-26T00:00:00.000Z","mah":"Meiji Seika Pharm","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Laserphyrin","application_number":"Laserphyrin"}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:14:54.484729+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}